Company / Operating Cash Flow per Share
Monopar Therapeutics Operating Cash Flow per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$2.00
FY2025
5-year range
-$2.64 / -$0.28
FY2021-FY2025
Trend
+24.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow per Share returned to growth in FY2025 after 3 years of decline, reaching $-2.00.
Based on SEC 10-K filings.
-2.00 in FY2025.
Declined from $-0.56 to $-2.00 over the past 2 years.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow per share increased 24.2% year-over-year.
- Peak operating cash flow per share was recorded in FY2018.
- Lowest operating cash flow per share in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 19.82 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.00 | +24.2% |
| FY2024 | -$2.64 | -372.2% |
| FY2023 | -$0.56 | -71.9% |
| FY2019 | -$0.32 | -14.9% |
| FY2018 | -$0.28 | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026